Coherus Oncology, Inc. (CHRS) vs LifeMD, Inc. (LFMDP)
A side-by-side comparison of Coherus Oncology, Inc. and LifeMD, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
LFMDP
LifeMD, Inc.
$21.70HealthcareDelayed quote: Oct 6, 2026, 11:23 AM EDT
Total return — CHRS vs LFMDP
growth of $100 · dividends reinvested · last 5yCHRS -93.2% (-41.6%/yr)LFMDP +67.0% (+10.8%/yr)LFMDP compounded faster over this window
Log scale — wide-divergence pair
CHRS LFMDP
CHRS vs LFMDP: by the numbers
- •CHRS is the larger company ($165M vs $148M market cap).
- •Both run net losses; LFMDP's is the smaller (-10.40% vs -257.10% net margin).
- •LFMDP grew revenue faster over the past five years (26.00% vs -33.60% CAGR).
- •LFMDP pays a dividend (9.71% yield), while CHRS has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | CHRS | LFMDP |
|---|---|---|
| P/S ratio | 3.23 | 0.72 |
| P/B ratio | 2.70 | 18.57 |
Profitability
| Metric | CHRS | LFMDP |
|---|---|---|
| Gross margin | 63.55% | 85.91% |
| Operating margin | -425.72% | -9.35% |
| Net margin | -257.10% | -10.40% |
| ROE | -215.26% | -266.86% |
| ROIC | -135.38% | -143.97% |
Dividends
| Metric | CHRS | LFMDP |
|---|---|---|
| Dividend yield | N/A | 9.71% |
Growth (annualized)
| Metric | CHRS | LFMDP |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | 26.00% |
| Total return CAGR (5Y) | -41.38% | 10.80% |
Frequently asked
- Which has grown faster, CHRS or LFMDP?
- Over the past five years, LFMDP grew revenue faster — CHRS at a -33.60% CAGR versus LFMDP at 26.00%.
- Does CHRS or LFMDP pay a bigger dividend?
- LFMDP pays a dividend (9.71% yield), while CHRS has no payments in the available dividend history.
- How have CHRS and LFMDP total returns compared?
- Over the past 5 years, CHRS delivered -41.38% and LFMDP delivered 10.80% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
LifeMD dividend yieldCoherus Oncology ROELifeMD ROECoherus Oncology operating marginLifeMD operating marginCoherus Oncology revenue growthLifeMD revenue growthCoherus Oncology free cash flowLifeMD free cash flow
Coherus Oncology & LifeMD appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.